Skip to main content
. 2023 Oct 19;146(6):837–840. doi: 10.1007/s00401-023-02642-5

Fig. 1.

Fig. 1

Graphical illustration of molecular data availability among EORTC 22042-26042 trial patients (a). Kaplan–Meier plots showing the impact of chromosome 1p (b), methylation class (c) and CDKN2A/B loss on progression-free survival (d)